2008
Gastric Mucosal Defense and Cytoprotection: Bench to Bedside
Laine L, Takeuchi K, Tarnawski A. Gastric Mucosal Defense and Cytoprotection: Bench to Bedside. Gastroenterology 2008, 135: 41-60. PMID: 18549814, DOI: 10.1053/j.gastro.2008.05.030.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsStress-related mucosal diseaseProton pump inhibitorsMucosal defenseGastric mucosal defenseMucosal injuryNoxious factorsNonsteroidal anti-inflammatory drugsCOX-2 selective inhibitorsGeneration of PGsImportant clinical sequelaeUpper gastrointestinal complicationsHigh-risk patientsModern intensive careAbsolute risk reductionInhibition of cyclooxygenaseAnti-inflammatory drugsContinuous blood flowGastrointestinal complicationsClinical sequelaePharmacologic therapyAntisecretory drugsSignificant bleedingAnnual incidenceIntensive careSensory innervation
2005
Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients
Conrad SA, Gabrielli A, Margolis B, Quartin A, Hata JS, Frank WO, Bagin RG, Rock JA, Hepburn B, Laine L. Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Critical Care Medicine 2005, 33: 760-765. PMID: 15818102, DOI: 10.1097/01.ccm.0000157751.92249.32.Peer-Reviewed Original ResearchConceptsUpper gastrointestinal bleedingSignificant upper gastrointestinal bleedingGastrointestinal bleedingIll patientsIntravenous cimetidineOmeprazole suspensionMedian gastricChronic Health Evaluation (APACHE II) scoreTrial daysOral suspensionCimetidine treatment groupsDouble-blind trialPrimary end pointDouble-blind comparisonIntensive care unitAdditional risk factorsAcute PhysiologyProtocol populationCimetidine treatmentMedication dosesOrogastric tubeSignificant bleedingCare unitMechanical ventilationGastric aspirates